Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease
Dominique P. Germain(Assistance Publique – Hôpitaux de Paris), William R. Wilcox(Emory University), Seymour Packman(University of California, San Francisco), David G. Warnock(University of Alabama at Birmingham), Roberta Lemay(Sanofi (United States)), C. Ronald Scott(University of Washington), Nathalie Guffon(Hôpital Edouard Herriot), Neal J. Weinreb, Stephen Waldek, Robert J. Desnick(Icahn School of Medicine at Mount Sinai), Judy Kempf, Gabor E. Linthorst(Geneeskundige en Gezondheidsdienst), Joel Charrow(Northwestern University), Robin Lachmann(University College London)
Cited by 363
Related Papers
Isolation of a candidate gene for Menkes disease and evidence that it encodes a copper–transporting ATPase
|Nature Genetics|1993|1.4k
Fabry disease
|Orphanet Journal of Rare Diseases|2010|1.2k
Elevated globotriaosylsphingosine is a hallmark of Fabry disease
|Proceedings of the National Academy of Sciences|2008|725
Agalsidase-Beta Therapy for Advanced Fabry Disease
|Annals of Internal Medicine|2007|565